FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board

KYNTRA BIO, INC.

Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.
Jeffrey L. Edwards re-elected as Class II director with 92.25% of votes cast.
Dr. Michael Kauffman appointed to board, will serve on Audit and Compensation Committees; term expires 2026.
Director Aoife Brennan resigned effective June 4, 2025, no disagreement with company.
Second amendment to financing agreement lowered minimum cash balance from $27M to $22.5M.

item 5.07item 5.02item 1.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Aoife Brennan

Director

KYNB · KYNTRA BIO, INC.

Effective: 2025-06-04
Filed: Jun 09, 2025 23:59 UTC

On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.

Appointed

Michael Kauffman

Class III director

KYNB · KYNTRA BIO, INC.

Effective: 2025-06-04
Filed: Jun 09, 2025 23:59 UTC

Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.

Source: SEC EDGAR

accession 0000950170-25-083676

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.